HOUSTON, Sept. 19, 2019 /PRNewswire/ -- Soliton,
Inc., (Nasdaq: SOLY) ("Soliton" or the "Company"), a medical device
company with a novel and proprietary platform technology licensed
from The University of Texas on behalf
of the MD Anderson Cancer Center ("MD Anderson"), today announced
that the company has begun treating patients in its
proof-of-concept trial for the treatment of keloid and hypertrophic
scars.
------------------------
Join our more than 200K fans here to
follow the Company: https://soly-investors.com
------------------------
Patient treatments have begun in the Company's proof-of-concept
clinical trial for the treatment of keloid and hypertrophic scars
at Clear Dermatology & Aesthetic Center in Scottsdale, AZ, by Dr. Brenda LaTowsky, Board Certified
Dermatologist.
"We are pleased to begin treatment on our first patients in this
trial evaluating the treatment for keloid scarring," said Dr.
Chris Capelli, President, CEO and
co-founder of Soliton. "This trial marks an important
milestone toward our goal of successful, non-invasive treatment for
the reduction of keloid and hypertrophic scars."
Keloid and hypertrophic scars represent wound healing gone
awry. A typical example would be a post-surgical scar that
grows beyond its boundaries. Existing published research
suggests that factors relating to the wound-healing environment
(including tension at the boundary of the scar) can cause
fibroblasts to become stuck in a hyper-productive loop, unable to
stop the production of collagen that leads to the thickened, raised
and dense structures often associated with these fibrotic
scars.
The American Osteopathic College of Dermatology estimates that
keloids affect around 10 percent of people,
whereas hypertrophic scars are more common. Keloid
scars are more prevalent among populations with darker
pigmentation. Hypertrophic scars affect men and women
from any racial group equally, although people between
the ages of 10 and 30 years old are more likely to be affected.
Market Research Futures estimates the global market for keloid
and hypertrophic scars may reach $3.9
billion by 2023. There are few treatment options
available for fibrotic scars, which in addition to being
disfiguring, can also cause significant discomfort.
Currently, the most common treatment is the direct injection of
steroids into the scar, however this can require multiple
injections and may not be a permanent solution.
In our press release dated September 17,
2019, regarding our keloid proof-of-concept study, we
mistakenly indicated that three additional trial sites would be
initiated. Only one site is involved in our current keloid
trial.
About Soliton, Inc.
Soliton, Inc. is a medical device company with a novel and
proprietary platform technology licensed from MD Anderson. The
Company's first FDA cleared commercial product will use rapid
pulses of acoustic shockwaves as an accessory to lasers for the
removal of unwanted tattoos. The Company is based in Houston, Texas, and is actively engaged in
bringing the Rapid Acoustic Pulse ("RAP") device to the market. The
Company believes this "Soliton" method has the potential to lower
tattoo removal costs for patients, while increasing profitability
to practitioners, compared to current laser removal methods.
Soliton is investigating potential additional capabilities of the
RAP technology in preclinical testing, including the potential to
assist existing fat reduction technology in the reduction of fat as
well as improving the appearance of cellulite by creating
mechanical stress at the cellular level and inducing significant
collagen growth.
For more information about the Company, please
visit: http://www.soliton.com
Forward-Looking Statements
Some of the statements in this release are forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933, Section 21E of the Securities Exchange Act of 1934 and the
Private Securities Litigation Reform Act of 1995, which involve
risks and uncertainties. Forward-looking statements in this press
release include, without limitation, the ability of the Soliton RAP
device to demonstrate safety and efficacy in the reduction of
keloid and hypertrophic scars, the ability of Soliton to complete
the proof-of-concept study, and the ability for Soliton to receive
FDA clearance for this additional indication. These statements
relate to future events, future expectations, plans and prospects.
Although Soliton believes that the expectations reflected in such
forward-looking statements are reasonable as of the date made,
expectations may prove to have been materially different from the
results expressed or implied by such forward-looking statements.
Soliton has attempted to identify forward-looking statements by
terminology including ''believes,'' ''estimates,'' ''anticipates,''
''expects,'' ''plans,'' ''projects,'' ''intends,'' ''potential,''
''may,'' ''could,'' ''might,'' ''will,'' ''should,''
''approximately'' or other words that convey uncertainty of future
events or outcomes to identify these forward-looking statements.
These statements are only predictions and involve known and unknown
risks, uncertainties, and other factors, including those discussed
under in our SEC filings, including under the heading "Item 1A.
Risk Factors" in the Form 10-K for year ended December 31, 2018 we filed with the SEC and
updated from time to time in our Form 10-Q filings and in our other
public filings with the SEC. Any forward-looking statements
contained in this release speak only as of its date. Soliton
undertakes no obligation to update any forward-looking statements
contained in this release to reflect events or circumstances
occurring after its date or to reflect the occurrence of
unanticipated events.
CONTACT:
|
Joe Dorame, Joe
Diaz & Robert Blum
|
|
Lytham Partners,
LLC
|
|
602-889-9700
|
|
soly@lythampartners.com
|
View original
content:http://www.prnewswire.com/news-releases/soliton-begins-treatments-in-proof-of-concept-trial-for-keloid-scars-300921453.html
SOURCE Soliton, Inc.